STOCK TITAN

Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) will participate in The Citizens JMP Life Sciences Conference on May 13, 2024. The management will engage in a fireside chat at 10:00 a.m. ET at the New York Hilton Midtown. The event will be live streamed on the company's website. A replay will be available for 1 year.

Positive
  • None.
Negative
  • None.

BOSTON--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens JMP Life Sciences Conference on Monday, May 13, 2024 at 10:00 a.m. ET at the New York Hilton Midtown.

A live audio webcast of Ironwood’s fireside chat will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. To access the webcast, please log on to the Ironwood website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Ironwood’s website for 1 year following the conference.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (Nasdaq: IRWD), an S&P SmallCap 600® company, is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. We are pioneers in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). LINZESS is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years-old. Ironwood is also advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for rare gastrointestinal diseases, including short bowel syndrome with intestinal failure (SBS-IF), as well as several earlier stage assets. Building upon our history of GI innovation, we keep patients at the heart of our R&D and commercialization efforts to reduce the burden of GI diseases and address significant unmet needs.

Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts, with a site in Basel, Switzerland.

We routinely post information that may be important to investors on our website at www.ironwoodpharma.com. In addition, follow us on Twitter and on LinkedIn.

Investors:

Greg Martini, 617-374-5230

gmartini@ironwoodpharma.com

Matt Roache, 617-621-8395

mroache@ironwoodpharma.com

Media:

Beth Calitri, 978-417-2031

bcalitri@ironwoodpharma.com

Source: Ironwood Pharmaceuticals, Inc.

FAQ

When will Ironwood Pharmaceuticals participate in The Citizens JMP Life Sciences Conference?

Ironwood Pharmaceuticals will participate in The Citizens JMP Life Sciences Conference on Monday, May 13, 2024.

Where will the fireside chat take place?

The fireside chat will take place at the New York Hilton Midtown.

How can I access the live audio webcast of Ironwood's fireside chat?

The live audio webcast will be accessible through the Investors section of Ironwood's website at www.ironwoodpharma.com.

Will there be a replay of the webcast available?

Yes, a replay of the webcast will be available on Ironwood's website for 1 year following the conference.

Ironwood Pharmaceuticals, Inc. -

NASDAQ:IRWD

IRWD Rankings

IRWD Latest News

IRWD Stock Data

718.11M
157.19M
1.68%
105.28%
5.35%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
BOSTON